Antagonism of estrogen receptor and calmodulin association by antiestrogens is not dependent on an interaction with calmodulin

Biochemical Pharmacology

Volumn 53, Issue 2, 1997, Pages 241-244

  Rowlands, Martin G ^a   Grimshaw, Rachel ^a   Jarman, Michael ^a   Bouhoute, Abdellah ^b   Leclercq, Guy ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

cAMP phosphodiesterase; steroidal antiestrogens; tamoxifen analogues; triphenylethylenes

Indexed keywords

CALMODULIN; CYCLIC AMP PHOSPHODIESTERASE; ESTRADIOL DERIVATIVE; ESTROGEN RECEPTOR; NAFOXIDINE; TAMOXIFEN;

ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; IN VITRO STUDY; PRIORITY JOURNAL;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; CALMODULIN; ESTROGEN ANTAGONISTS; RECEPTORS, ESTROGEN; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0031029244     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00603-X     Document Type: Article

References (19)

1. 2+ -calmodulin. Mol Endocrinol 2: 167-174, 1988.
2. Bouhoute A and Leclercq G, Antagonistic effect of triphenylethylenic antiestrogens on the association of estrogen receptor to calmodulin. Biochem Biophys Res Commun 184: 1432-1440, 1992.
3. Lam HYP, Tamoxifen is a calmodulin antagonist in the activation of cyclic AMP phosphodiesterase. Biochem Biophys Res Commun 118: 27-32, 1984.
4. Fanidi A, Guichard Y, Fayard JM, Pageaux JF and Laugier C, Fluorimetric studies of calmodulin interactions with antiestrogens. Cancer Detect Prevent 18: 471-478, 1994.
5. 2+ -dependent binding of tamoxifen to calmodulin isolated from bovine brain. Cancer Res 50: 2753-2758, 1990.
6. Rowlands MG, Parr IB, McCague R, Jarman M and Goddard PM, Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen; correlations with cytotoxicity. Biochem Pharmacol 40: 283-289, 1990.
7. Jordan VC and Gosden B, Importance of the alkylaminoethoxy side chain for estrogenic and antiestrogenic actions of tamoxifen and trioxifene in the mature rat uterus. Mol Cell Endocrinol 27: 291-306, 1982.
8. Murphy LC and Sutherland RL, Differential effects of tamoxifen and analogs with non-basic side chain on cell proliferation in vitro. Endocrinology 116: 1071-1978, 1985.
9. Jin L, Borras M, Lacroix M, Legros N and Leclercq G, Antiestrogenic activity of two 11 β-estradiol derivatives on MCF-7 breast cancer cells. Steroids 60: 512-518, 1995.
10. Gottardis MM, Jiang SY, Jeng MH and Jordan VC, Inhibition of tamoxifen-stimulated growth of a MCF-7 tumour variant in athymic mice by novel steroidal antiestrogens. Cancer Res 49: 4090-4093, 1989.
11. Nique F, Nedelec L, Bouton MM and Philibert D, New 7-aryl-substituted, 19 norsteroids useful as proliferative, antiestrogens and/or estrogens and their preparation, use as medicines and pharmaceutical compositions. Eur. Patent Appl. EP 280,618(31/08/1988). Chemical Abstr 110: 115181, 1989.
12. Bouhoute A and Leclercq G, Estradiol derivatives bearing the side chain of tamoxifen antagonise the association between the estrogen receptor and calmodulin. Biochem Pharmacol 47: 748-751, 1994.
13. McCague R, Leclercq G, Legros N, Goodman J, Blackburn GM, Jarman M and Foster AB, Derivatives of tamoxifen. Dependence of antiestrogenicity on the 4-substituent. J Med Chem 32: 2527-2533, 1989.
14. Hardcastle IR, Rowlands MG, Grimshaw R, Houghton J, Jarman M, Sharff A and Neidle S. Homologs of idoxifene: Variation of estrogen receptor binding and calmodulin antagonism with chain lengths. J Med Chem 39: 999-1004, 1996.
15. McCague R, Kuroda R, Leclercq G and Stoessel S, Synthesis and estrogen receptor binding of 6,7-dihydro-8-phenyl-9-[4-[2-(dimethylamino)ethoxy]phenyl]-5H-benzocycloheptene. J Med Chem 29: 2053-2059, 1986.
16. McCague R, Rowlands MG, Grimshaw R and Jarman M, Evidence that tamoxifen binds to calmodulin in a conforma-tion different to that when binding to estrogen receptors, through structure-activity study on ring-fused analogues. Biochem Pharmacol 48: 1355-1361, 1994.
17. MacNeil S, Dawson RA, Crocker G, Tucker WFG, Bittiner B, Singleton JG, Hunter T and Tierney DF. Antiproliferative effects on keratinocytes of a range of clinically used drugs with calmodulin antagonist activity. Br J Dermatol 28: 143-150, 1993.
18. Berthois Y, Pons M, Dussert C, Paulet AC and Martin PM, Agonist-antagonist activity of antiestrogens in the human breast cancer cell line MCF-7: A hypothesis for the interaction with a site distinct from the estrogen binding site. Mol Cell Endocrinol 99: 259-268, 1992.
19. Hedden A, Muller V and Jensen EV, A new interpretation of antiestrogen action. In: Steroid Receptors and Antihormones; Annals of the New York Academy of Science (Eds. Henderson D, Philibert D, Roy A and Teutsch G), pp. 109-120. New York Academy of Science, New York, 1995.